2008 Update From the Collaborative Islet Transplant Registry

  title={2008 Update From the Collaborative Islet Transplant Registry},
  author={Rodolfo Alejandro and Franca B. Barton and Bernhard J. Hering and Stephen Wease},
Background. This report summarizes the primary efficacy and the safety outcomes of islet transplantation reported to the NIDDK and JDRF funded Collaborative Islet Transplant Registry (CITR), currently the most comprehensive collection of human-to-human islet transplant data. Methods. CITR collects and monitors comprehensive data on allogeneic islet transplantation in North America, Europe, and Australia since 1999. Results. As of April 2008, the CITR registry comprised 325 adult recipients of… 

HLA Class I Sensitization in Islet Transplant Recipients: Report from the Collaborative Islet Transplant Registry 1

Pre- and posttransplant human leukocyte antigen (HLA) class I sensitization rates in islet-alone transplantation are presented and the risk of sensitization may be reduced by minimizing the number of islet donors used per recipient, and in the absence of donor-specific anti-HLA antibodies.

Improvement in Outcomes of Clinical Islet Transplantation: 1999–2010

The CITR shows improvement in primary efficacy and safety outcomes of islet transplantation in recipients who received transplants in 2007–2010 compared with those in 1999–2006, with fewer islet infusions and adverse events per recipient.

Islet Transplantation Using Donors After Cardiac Death: Report of the Japan Islet Transplantation Registry

Islet transplantation employing DCD can ameliorate severe hypoglycemic episodes, significantly improve HbA1c levels, sustain significant levels of C-peptide, and achieve insulin independence after multiple transplantations, particularly in countries where heart-beating donors are not readily available.

Combined Kidney-Islet Transplantation

The global long-term results of CITR demonstrated an insulin independence after islet transplantation in a low percentage of cases but a partial function of the graft, and consequently important advantages for the patients, in the majority of these.

Adverse Events in Clinical Islet Transplantation: One Institutional Experience

Need to improve both infusion procedure and immunosuppressive strategy from the view of preventing SAEs is suggested.

Rescue of a pancreatic islet graft after steroid therapy.

The decline of islet function in an islet transplant recipient and the recovery of the graft after steroid bolus therapy is documented and a diagnosis of acute cellular islet rejection was proposed.

A Multicenter Study: North American Islet Donor Score in Donor Pancreas Selection for Human Islet Isolation for Transplantation

The North American Islet Donor Score (NAIDS), developed with the aid of univariate logistic regression analyses, may be a useful tool for donor pancreas selection in clinical practice and may also be used in a research setting as a standardized measurement of Pancreas quality.

Evolution of Islet Transplantation for the Last 30 Years

With improved islet isolation techniques and determination of the best site of engraftment as well as improved encapsulation techniques, it is hoped that islet transplantation could someday achieve routine clinical use.

Stem Cells as a Tool to Improve Outcomes of Islet Transplantation

The manners in which stem cells have been applied to address barriers to the achievement of long-term insulin independence following islet transplantation are outlined.

Validation of a New North American Islet Donor Score for Donor Pancreas Selection and Successful Islet Isolation in a Medium-Volume Islet Transplant Center

North American Islet Donor Score was found to be the most useful available tool for donor pancreas selection in clinical and research practice in the authors' center, allowing for identification and rejection of poor-quality donors, saving time and resources.



The Islet Transplant Experiment: Time for a Reassessment

Sober reassessment of the clinical applicability of this protocol and particular experiment is needed because of the continued insulin dependence, the shortage of donor organs, the complications of immunosuppression, and the great expense of this procedure.

International Trial of the Edmonton Protocol for Islet Transplantation

Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.

The observations in patients with type 1 diabetes indicate that islet transplantation can result in insulin independence with excellent metabolic control when glucocorticoid-free immunosuppression is combined with the infusion of an adequate islet mass.